NORWALK, Conn.--(BUSINESS WIRE)--There may be no bigger commercial issue for the biopharmaceutical sector than the question of whether and how the Food & Drug Administration (FDA) will allow an abbreviated shortcut to market for follow-on biologic products. Windhover’s FDA/CMS Summit, to take place Dec. 4-5 in Washington, DC, will bring together key stakeholders and experts to discuss the prospects for new legislation and regulatory approaches and business implications for companies in this dynamic environment
